Tags

Type your tag names separated by a space and hit enter

Treatment strategies for CML.
Best Pract Res Clin Haematol 2009; 22(3):303-13BP

Abstract

Little important progress was made in terms of prolongation of life for patients with chronic myeloid leukaemia (CML) until the advent of interferon-alpha and allogeneic stem cell transplantation in the 1980s. However, in 1998 the introduction of imatinib, the first tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL1 oncoprotein, has fundamentally altered treatment strategies for patients in all phases of CML. Imatinib is now recommended as initial treatment for all patients who present in chronic phase (CP) and about two-thirds of patients so treated will be in continuing complete cytogenetic response 7 or more years after starting therapy. A small proportion of these patients can stop the drug without molecular evidence of relapse. For the minority of patients who are judged to have failed initial treatment with imatinib at standard dosage or increased dosage, the use of second-generation TKI or allogeneic stem cell transplantation must be considered.

Authors+Show Affiliations

Department of Haematology, Imperial College London, Du Cane Road, London W12 0NN, UK. jgoldman@imperial.ac.uk

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19959082

Citation

Goldman, John M.. "Treatment Strategies for CML." Best Practice & Research. Clinical Haematology, vol. 22, no. 3, 2009, pp. 303-13.
Goldman JM. Treatment strategies for CML. Best Pract Res Clin Haematol. 2009;22(3):303-13.
Goldman, J. M. (2009). Treatment strategies for CML. Best Practice & Research. Clinical Haematology, 22(3), pp. 303-13. doi:10.1016/j.beha.2009.08.001.
Goldman JM. Treatment Strategies for CML. Best Pract Res Clin Haematol. 2009;22(3):303-13. PubMed PMID: 19959082.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment strategies for CML. A1 - Goldman,John M, PY - 2009/12/5/entrez PY - 2009/12/5/pubmed PY - 2010/2/24/medline SP - 303 EP - 13 JF - Best practice & research. Clinical haematology JO - Best Pract Res Clin Haematol VL - 22 IS - 3 N2 - Little important progress was made in terms of prolongation of life for patients with chronic myeloid leukaemia (CML) until the advent of interferon-alpha and allogeneic stem cell transplantation in the 1980s. However, in 1998 the introduction of imatinib, the first tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL1 oncoprotein, has fundamentally altered treatment strategies for patients in all phases of CML. Imatinib is now recommended as initial treatment for all patients who present in chronic phase (CP) and about two-thirds of patients so treated will be in continuing complete cytogenetic response 7 or more years after starting therapy. A small proportion of these patients can stop the drug without molecular evidence of relapse. For the minority of patients who are judged to have failed initial treatment with imatinib at standard dosage or increased dosage, the use of second-generation TKI or allogeneic stem cell transplantation must be considered. SN - 1532-1924 UR - https://www.unboundmedicine.com/medline/citation/19959082/Treatment_strategies_for_CML_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1521-6926(09)00056-5 DB - PRIME DP - Unbound Medicine ER -